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Objective: This trial investigated the efficacy and safety of the
SQ HDM SLIT-tablet in adults with moderate-to-severe
HDM-induced allergic rhinitis (AR).
Methods: The trial was a randomized, double-blind, placebo-
controlled phase III trial conducted in 12 European countries
including 992 adults with moderate-to-severe HDM-induced AR
despite treatment with pharmacotherapy. Subjects were
randomized 1:1:1 to 1 year of daily treatment with placebo, 6 SQ-
HDM, or 12 SQ-HDM. The primary end point was the total
combined rhinitis score (ie, the sum of rhinitis symptom and
medication scores) during the efficacy assessment period
(approximately the last 8 weeks of the treatment period). Key
secondary end points were rhinitis symptoms, medication scores,
quality of life, and the combined rhinoconjunctivitis score.
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4441.18 (P5 .002) and 1.22 (P5 .001) comparedwith placebo for 6 SQ-
HDM and 12 SQ-HDM, respectively. The statistically significant
treatment effect was evident from 14 weeks of treatment onward.
For all key secondary end points, efficacy was confirmed for 12 SQ-
HDM, with statistically significant reductions of rhinitis symptoms
and medication scores, improved quality of life, and a reduced
combinedrhinoconjunctivitis score in the efficacyassessmentperiod
compared with placebo. The treatment was well tolerated.
Conclusion: The trial confirmed the efficacy and favorable
safety profile of both 6 SQ-HDM and 12 SQ-HDM in adults with
HDM-induced AR. The treatment effect was present from
14 weeks of treatment onward. (J Allergy Clin Immunol
2016;137:444-51.)
Key words: Allergy immunotherapy, sublingual immunotherapy
tablet, sublingual immunotherapy, allergen immunotherapy, allergy,
allergic rhinitis, house dust mite, Rhinitis Quality of Life Question-
naire, rhinoconjunctivitis, total combined rhinitis score
Allergic rhinitis (AR) is estimated to affect 17% to 29% of the
population across Europe1 and is found in subjects of all ethnic-
ities and ages. Allergy to house dust mite (HDM) is the most com-
mon inhalant allergy,2 with sensitization in 49% of subjects with a
clinical diagnosis of AR in Western Europe.1 HDM-induced AR
is also associated with an increased risk of asthma,3 and perennial
exposure toHDMallergensmight lead tomore chronic and severe
symptoms compared with other aeroallergens.4 In the European
Community Respiratory Health Survey, including 1132 adults
with current asthma, 48% had a positive skin prick test response
to HDM allergens.5
HDM-induced AR can be treated with pharmacotherapy,
including oral antihistamines and nasal steroids. However, in-
vestigations suggest that a substantial portion of patients’ symp-
toms are inadequately controlled,6 and allergen avoidance is not
possible to an extent that relieves patients of their symptoms.7
Allergy immunotherapy (AIT) is a treatment option that is
complementary to pharmacotherapy and has a distinct mecha-
nism of action. AITmodulates basic immunologicmechanisms of
the allergic disease and is recognized as the only treatment option
with the potential to provide long-term posttreatment benefits and
alter the natural course of allergic disease.8 Subcutaneous AIT has
been shown to decrease symptoms in patients with HDM-induced
AR.9-11 However, sublingual allergy immunotherapy (SLIT) is
more convenient because of home administration and is
associated with fewer and less severe adverse events (AEs) than
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concludes that reported results have been variable and that there
is a need for more rigorous studies assessing standardized efficacy
outcomes, treatment duration, and dose.13 Furthermore, there is a
large variation in the quality and standardization of currently
available SLIT products.13
A recently published phase II trial with the SQ HDM SLIT-
tablet (ALK, Hørsholm, Denmark) showed a beneficial effect on
combined rhinitis symptom and medication scores in a subgroup
of asthmatic patients with symptomatic AR at inclusion.14
Subsequently, the current phase III trial was initiated to confirm
the efficacy of the highly standardized SQ HDM SLIT-tablet in
subjects with moderate-to-severe AR.
METHODS
Ethics
The trial is identified by EudraCT number 2011-002277-38 and
ClinicalTrials.gov Identifier NCT01454544. The trial was designed and con-
ducted in accordance with the principles of the Declaration of Helsinki15 and
conducted in compliance with the principles of the International Conference
on Harmonization of Technical Requirement for Registration of Pharmaceu-
ticals for Human Use (ICH) Good Clinical Practice.16
Trial design
This was a randomized, parallel-group, double-blind, placebo-controlled,
multinational, multisite trial in Europe. The trial included 100 sites in 12
countries. In total, 992 subjects were randomized 1:1:1 to receive treatment
with the SQ HDM SLIT-tablet in doses of 6 SQ-HDM or 12 SQ-HDM or with
placebo for approximately 12 months. The trial design is shown in Fig 1.
Trial population
The trial population comprised adults 18 to 65 years of agewith moderate-to-
severe HDM-induced AR (with or without asthma and conjunctivitis) despite
having received pharmacotherapy (further description of the trial population and
main selection criteria can be found in theMethods section in this article’sOnline
Repository at www.jacionline.org). Data on rhinitis symptoms and medication
use were collected during the baseline period to confirm that subjects had
moderate-to-severe HDM-induced AR. Moderate-to-severe HDM-induced AR
symptoms were defined by a daily total rhinitis symptom score of at least 6 or
a score of at least 5 with 1 severe symptom during at least 8 days of the 15-
day baseline period. Furthermore, subjects should report use of pharmacotherapy
for treatment of HDM-induced AR during at least 8 days of the 15-day baselineperiod. If the patient had asthma, daily use of inhaled corticosteroids (ICSs) dur-
ing the baseline period should be 400 mg of budesonide or less or equivalent (ie,
corresponding to Global Initiative for Asthma treatment steps 1 or 2). Subjects
were allowed to increase this dose during the study, if needed.
Intervention medication
Each subject was randomly assigned to receive one of 2 active doses (SQ
HDM SLIT-tablet) or placebo. The first dose was administered under medical
supervision lasting at least 30 minutes after tablet intake. Subjects were
instructed to take 1 tablet sublingually daily. The SQHDMSLIT-tablet is a 1:1
mixture of allergen extracts derived from 2 species of cultivated HDM
(Dermatophagoides pteronyssinus and Dermatophagoides farinae) through a
highly standardized production process, leading to a 1:1:1:1 ratio of the major
allergens Der p 1, Der f 1, Der p 2, and Der f 2. The intervention medication
was provided and manufactured by the trial sponsor (ALK). The placebo tab-
lets were similar to the active intervention medication with regard to appear-
ance, smell, and taste.
Pharmacotherapy for AR, conjunctivitis, or both (ie, antihistamine tablets
and eye drops or nasal steroids) was provided by ALK to subjects at
randomization as predefined open-label medication to be used freely in
addition to the intervention medication to which the subjects had been
randomized (details on pharmacotherapy can be found in the Methods section
in this article’s Online Repository).
Randomization
Randomization was performed according to a sponsor-generated allocation
schedule by a trial-independent statistician. Randomization was stratified by
sites using block randomization. Details on randomization are provided in the
Methods section in this article’s Online Repository.
End points and assessments
Subjects were instructed on how to complete symptom and medication
assessments and record results in an electronic diary every morning during the
baseline period (15 days), during 1week after visits 3 to 6 (weeks 4, 14, 24, and
34), and during the efficacy assessment period (the last approximately 8 weeks
of the 1 year treatment period, Fig 1). The efficacy assessment period took
place betweenOctober 1 andMarch 15 to avoid overlapping symptoms caused
by pollen allergy.
A total of 6 allergic symptoms, 4 rhinitis symptoms (runny nose, blocked
nose, sneezing, and itchy nose), and 2 conjunctivitis symptoms (gritty feeling/
red/itchy eyes and watery eyes) were measured on a scale from 0 to 3 (ie, no to
severe symptoms). For the medication score, subjects reported their use of
specific pharmacotherapy. The primary end point was the total combined
rhinitis score (TCRS; ie, the sum of rhinitis symptom and medication score
[range, 0-24]). Details of scoring scales are provided in Table E1 in this
article’s Online Repository at www.jacionline.org.
Disease-specific quality of life was assessed by using the Rhinoconjuncti-
vitis Quality of Life Questionnaire with Standardised Activities (RQLQ),
which was included in the subject’s diary.17
Immunologic parameters were assessed to confirm the diagnosis and
evaluate the specific immunologic response to treatment (full results to be
published separately). AEs were recorded from when the subjects signed the
informed consent form until the last follow-up visit.
Statistical methodology
A sample size of 300 per treatment group was determined by using
computer simulations (see Table E2 in this article’s Online Repository at
www.jacionline.org for details of power calculation). The primary analysis
compared treatment groups by using a linear mixed effects (LME) model,
including the average AR symptoms score at baseline as a fixed effect and
country as a random effect.
The full analysis set included all randomized subjects in accordance with
the ICH intent-to-treat principle. The primary analysis set was the full analysis
set with multiple imputations for missing data (FAS-MI), which conserva-
tively treated all subjects with missing data as having no treatment effect.
FIG 1. Overall trial design. Subjects were treated for approximately
12 months. The subjects filled in an electronic diary during 1 week after
each visit and daily during the last 8 weeks of treatment (efficacy
assessment period).
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analysis set, observed data (FAS), and on the per-protocol (PP) analysis set.
Key secondary end points were similarly analyzed by means of LME models
on FAS-MI and FAS. Multiplicity for the primary and key secondary analyses
were controlled for by using the Fisher least significant difference procedure
and a hierarchic testing strategy. All other statistical hypotheses were not
controlled for multiplicity and are explorative in nature. An absolute
difference in TCRS means between active treatment and placebo of 1 was
predefined as the minimal clinically relevant difference based on what this
difference could mean to the patient and further supported by results from
previous trials with 2 authorized pollen SLIT-tablet products.18-23
Further details regarding statistical analyses are reported in the Methods
section in this article’s Online Repository.RESULTS
Population
An overview of subject disposition is shown in Fig 2. No
overall differences were seen between groups in numbers ofFIG 2. Subject disposition showing number of screene
reasons for discontinuations.discontinuations. However, a slightly higher proportion of sub-
jects discontinued because of AEs in the active groups (6
SQ-HDM, 3%; 12 SQ-HDM, 4%) compared with the placebo
group (2%).
Subjects’ demographics and baseline characteristics are
presented in Table I. The 3 treatment groups were similar with
regard to sex distribution, different ethnic origin, and smoking
history.
In accordance with the inclusion criteria, all subjects had
moderate-to-severe HDM-induced AR. The proportion of poly-
sensitized subjects was 68%, and main cosensitizations based on
skin prick tests were as follows: grass pollen, 41%; cat, 41%; dog,
28%; and birch pollen, 22%. In addition, 46% of the population
had concomitant HDM-induced allergic asthma. On average, the
subjects had HDM-induced AR for 10 years, with no overall
differences between groups. At baseline, the 3 groups were
similar with regard to rhinitis, conjunctivitis, and rhinoconjuncti-
vitis symptom scores (data not shown), as well as the extent and
type of pharmacotherapy used (data not shown).Efficacy in patients with AR
The primary end point was the TCRS averaged over the last
8 weeks of treatment. Results of the statistical analysis are shown
in Table II.
For the FAS, the absolute reduction in the TCRS compared
with the placebo group was 1.18 (P 5 .002) for the 6 SQ-HDM
group and 1.22 (P 5 .001) for the 12 SQ-HDM group. The pri-
mary analysis on FAS-MI showed a statistically significant dif-
ference from placebo for both active groups, being greater than
the prespecified clinical relevance criterion of an absolute differ-
ence of 1 compared with placebo. Relative differences from the
placebo group in TCRS by using adjusted means and medians
when analyzed on FAS and PP ranged from 18% to 22%
(Table III). The difference from placebo was numerically higher
for the 12 SQ-HDM group than for the 6 SQ-HDM group,d, randomized, and completed subjects, as well as












HDM-induced AR, no. (%) 338 (100) 336 (100) 318 (100) 654 (100) 992 (100)
Years with HDM-induced AR, mean (SD) 10.0 (8.7) 10.0 (9.1) 9.8 (8.1) 9.9 (8.6) 9.9 (8.7)
HDM-induced allergic asthma, no. (%) 152 (45) 152 (45) 152 (48) 304 (46) 456 (46)
Sensitization status, no. (%)
Monosensitized 106 (31) 98 (29) 109 (34) 207 (32) 313 (32)
Polysensitized 232 (69) 238 (71) 209 (66) 447 (68) 679 (68)
Sex, no. (%)
Male 166 (49) 165 (49) 163 (51) 328 (50) 494 (50)
Female 172 (51) 171 (51) 155 (49) 326 (50) 498 (50)
Age (y)
Mean (SD) 32.2 (10.9) 32.5 (11.2) 32.1 (10.6) 32.3 (10.9) 32.3 (10.9)
Median 29.0 30.0 30.0 30.0 30.0
Minimum-maximum 18.0-66.0 18.0-66.0 18.0-63.0 18.0-66.0 18.0-66.0
Ethnic origin, no. (%)
White 331 (98) 330 (98) 314 (99) 644 (98) 975 (98)
Asian 1 (<1) 1 (<1) 1 (<1) 2 (<1) 3 (<1)
African 1 (<1) 1 (<1) — 1 (<1) 2 (<1)
Hispanic 1 (<1) — 1 (<1) 1 (<1) 2 (<1)
Other 4 (1) 4 (1) 2 (<1) 6 (<1) 10 (<1)
Smoking history, no. (%)
Nonsmoker 272 (80) 275 (82) 261 (82) 536 (82) 808 (81)
Previous smoker 30 (9) 29 (9) 26 (8) 55 (8) 85 (9)
Smoker 36 (11) 32 (10) 31 (10) 63 (10) 99 (10)
TABLE II. Analysis of the primary end point
Analysis set Treatment No. TCRS adjusted means Difference from placebo (95% CI) P value
FAS-MI Global null hypothesis (placebo 5 6 SQ-HDM 5 12 SQ-HDM) .003
Placebo 338 6.81 — —
6 SQ-HDM 336 5.74 1.07 (0.34-1.80) .004
12 SQ-HDM 318 5.71 1.09 (0.35-1.84) .004
FAS Placebo 298 6.76 — —
6 SQ-HDM 297 5.58 1.18 (0.45-1.91) .002
12 SQ-HDM 284 5.53 1.22 (0.49-1.96) .001
The prespecified criterion for clinical relevance was a difference from placebo of 1 or greater in TCRS.
TABLE III. Relative differences for the primary end point (TCRS) for the FAS and PP analysis set during the efficacy assessment
period
Analysis set Treatment No. TCRS Absolute difference from placebo Relative difference to placebo
PP set, adjusted means Placebo 272 6.74 — —
6 SQ-HDM 269 5.53 1.20 18%
12 SQ-HDM 264 5.38 1.36 20%
PP set, medians Placebo 272 7.45 — —
6 SQ-HDM 269 5.91 1.54 21%
12 SQ-HDM 264 5.79 1.66 22%
FAS, adjusted means Placebo 298 6.76 — —
6 SQ-HDM 297 5.58 1.18 18%
12 SQ-HDM 284 5.53 1.22 18%
FAS, medians Placebo 298 7.54 — —
6 SQ-HDM 297 6.20 1.34 18%
12 SQ-HDM 284 5.88 1.66 22%
The PP set indicates all subjects with no major protocol deviations (defined before unblinding).
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ferences were comparable between the 2 dose groups. The results
were consistent regardless of analysis set and parameters used
(adjusted means or medians). Post hoc subgroup analyses ofthe primary end point showed that there was no statistically sig-
nificant difference between the treatment effect in patients with
asthma versus no asthma and monosensitized versus polysensi-
tized subjects (data not shown).
FIG 3. Adjusted means of the TCRS and overall RQLQ(s) score over time for the 3 treatment groups (FAS).
Error bars represent pairwise comparisons between each of the active dose and placebo groups. Asterisks
designate statistically significant differences from placebo.
TABLE IV. Key secondary results for FAS during the efficacy assessment period
Key secondary end point Treatment No. Adjusted means Absolute difference (95% CI) P value
AR symptoms score Placebo 298 3.30 — —
6 SQ-HDM 297 2.90 0.40 (0.03 to 0.76) .032
12 SQ-HDM 284 2.76 0.54 (0.18 to 0.89) .003
AR medication score Placebo 298 2.83 — —
6 SQ-HDM 297 2.13 0.69 (0.18 to 1.20) .008
12 SQ-HDM 284 2.22 0.60 (0.08 to 1.13) .024
Overall RQLQ score Placebo 240 1.58 — —
6 SQ-HDM 242 1.45 0.13 (20.05 to 0.31) .162
12 SQ-HDM 229 1.38 0.19 (0.02 to 0.37) .031
Combined rhinoconjunctivitis score Placebo 257 9.12 — —
6 SQ-HDM 256 7.74 1.38 (0.32 to 2.45) .011
12 SQ-HDM 241 7.91 1.21 (0.13 to 2.28) .029
Boldface numbers indicate a confirmatory result according to the multiplicity adjusting procedure.
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of the trial (FAS). For both active doses, a statistically significant
difference from placebo of 1 or greater (prespecified criterion for
clinical relevance) was seen from week 14 and throughout the
1-year treatment period. The analysis of the primary end point
for each active dose group is represented by the point at 44 to
52 weeks with treatment.
Key secondary end points are AR symptom, AR medication,
RQLQ, and total rhinoconjunctivitis scores averaged over the
last 8 weeks of treatment. Analyses on FAS are presented in
Table IV, whereas results based on FAS-MI are reported in
Table E3 in this article’s Online Repository at www.
jacionline.org. For 12 SQ-HDM, efficacy was confirmed for
all 4 key secondary end points, whereas for 6 SQ-HDM,
efficacy could only be confirmed for AR symptoms/medication
scores.
Fig 4 shows the adjusted mean values of the individual com-
ponents of the AR symptom and RQLQ scores. For all parame-
ters, numerically lower scores were observed for the actively
treated groups compared with the placebo group, and generally,
a dose response was seen. For the 6 SQ-HDM group, the differ-
ence from placebo was statistically significant for blocked nose.For the 12 SQ-HDM group, the difference from placebo was
statistically significant for all 4 individual AR symptoms and
for 4 of the 7 RQLQ domains: nasal symptoms, nonnose/noneye
symptoms, practical problems, and sleep impairment. Fig 3
shows the overall RQLQ score plotted versus time and by treat-
ment group. The difference from placebo was more pronounced
for the 12 SQ-HDM group compared with the 6 SQ-HDM group
and was statistically significant at weeks 24 and 44 to 54. The
change from baseline on overall RQLQ scores with the 12
SQ-HDM dose was 1.91 compared with 1.71 with placebo
(P 5 .031).
Analysis of other secondary end points, including rhinocon-
junctivitis symptom and medication scores, conjunctivitis scores,
symptom-free days, and global evaluation during the efficacy
assessment period, are shown in Tables E4 and E5 in this article’s
Online Repository at www.jacionline.org. In general, the results
were favorable for the actively treated groups compared with
placebo in all these end points, with statistically significant
differences from placebo seen in rhinoconjunctivitis symptom
scores (12 SQ-HDM group), rhinoconjunctivitis medication
scores (6 SQ-HDM group), symptom-free days (6 and 12
SQ-HDM groups), and global evaluations (6 SQ-HDM group).
FIG 4. Individual components of the AR symptom and RQLQ(S) scores in the efficacy assessment period.
Scores are shown as adjusted means. Asterisks designate statistically significant differences from placebo.
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In general, the intervention medication was well tolerated.
Most AEs observed during the trial were mild local allergic
reactions (an overview of AEs can be found in Table E6 in this ar-
ticle’s Online Repository at www.jacionline.org). The majority of
these local allergic reactions occurred within the first few days,
and each event typically subsided again within a few days or
weeks with continued treatment depending on the type of local re-
action. The most common AEs reported as being related to the
investigational medicinal product (IMP) by the investigator
were oral pruritus, throat irritation, and mouth edema (20%,
14%, and 8% of subjects on active treatment, respectively).
Twelve serious adverse events were reported in 12 subjects during
the trial: 8 subjects from the placebo group and 4 subjects from the
6 SQ-HDM group. None of the serious AEs were assessed as be-
ing related to the IMP by the investigator. One subject from the 12
SQ-HDM group received adrenaline after the first tablet because
of mild laryngeal edema (palatine and oropharyngeal pruritus,
followed by dysphonia, throat irritation, and dry cough). The sub-
ject subsequently continued and completed the trial without other
AEs, except for mild oral pruritus (further description of this case
can be found in the Results section in this article’s Online
Repository at www.jacionline.org). No AEs were reported as
systemic allergic reaction in any of the groups.DISCUSSION
This randomized, double-blind, placebo-controlled phase III
trial with the SQ HDM SLIT-tablet revealed a statistically
significant reduction in TCRSs in patients with moderate-to-
severe HDM-induced AR, with simultaneous reductions of both
symptoms and medication use. Consequently, the patients
receiving active treatment had fewer symptoms, even though
they used less pharmacotherapy to reduce them, an effect
consistent across all analysis sets. The difference from placebo
reached statistical significance and met the prespecified criterion
for clinical relevance (TCRS >_1) for both actively treated groups
after 14 weeks of treatment. A statistically significant difference
of greater than 1 was observed for all subsequent assessmentpoints during the 1-year treatment period, with the magnitude of
effect increasing until week 24, after which it remained constant.
This supports the findings in 2 previous phase II trials with the SQ
HDM SLIT-tablet. The first trial was a phase II in-field trial in
which TCRSs were shown to be significantly reduced by 6 SQ-
HDM in a post hoc analysis on a subgroup of asthmatic patients
with mild-to-moderate HDM-induced AR.24 The second trial
showed a significant dose-related reduction in total nasal symp-
tom scores in patients with HDM-induced AR by using an exper-
imental exposure chamber with statistically significant effect in
the 12 SQ-HDM group already after 8 weeks of treatment.25
Despite differences in scoring scales, the presented results are
also in accordance with what were found in a recently reported
trial assessing the efficacy and safety of 2 doses of a different
HDM SLIT-tablet in 509 subjects with moderate-to-severe
HDM-induced AR.26 In this trial both tested doses significantly
improved the primary end point of average adjusted symptom
score (total symptoms score adjusted for pharmacotherapy
use).26 In the current trial differences in both AR symptom and
medication scores were statistically significant for both active
doses compared with placebo, in contrast to the trial by Bergman
et al,26 in which no significant difference could be seen for the
medication score. The current trial only included patients that re-
ported use of pharmacotherapy for treatment of HDM-induced
AR during at least 8 days of the 15-day baseline period, which
resulted in a population with a significantly higher medication
score, indicating high disease severity.
It is widely acknowledged that the use of pharmacotherapy has
an effect on symptom scores. Therefore the current trial uses a
combined symptom and medication score (TCRS) in accordance
with current guidelines.27,28 One potential weakness of medica-
tion scores is a lack of standardized measures for assessing daily
medication use.29,30 The medication score used in the current trial
is similar to what had been used in other trials with the SQ HDM
SLIT-tablet and in trials with the authorized product Grazax
(ALK). More recently, a European Academy of Allergy and
Clinical Immunology position paper has been published,31
suggesting a more standardized model to score daily medication
use, which could be considered in future trials.
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clinically relevant effect for immunotherapy as being 20% or
greater of the relative difference from placebo.32 However,
relative differences per se cannot be used as a sole measure of
clinical relevance and need to be seen in context with the numeric
size of the TCRS onwhich the relative differences are based. Thus
relative differences depend not only on the absolute difference
between groups but also on the absolute TCRS of the placebo
group and hence on the disease severity of the investigated popu-
lation. In the current trial the relative difference from placebo for
12 SQ-HDM was 22% for FAS by using medians (data not
normally distributed), supporting the clinical relevance of the
observed effect, especially when taking the high disease severity
into account. All subjects had free access to pharmacotherapy in
addition to the IMP. Therefore the effect measured in this trial
provides an additional benefit to guided and free access to
guideline-recommended pharmacotherapy. The added benefit
provided by the SQ HDM SLIT-tablet is supported by the
RQLQ results, which showed (1) an improvement from baseline
to the end of treatment in the placebo group of more than 3 times
the published minimal clinically important difference of 0.5
within a patient17 and (2) an additional improvement for 12
SQ-HDM compared with placebo. This effect was obtained
even though patients also reduced their need for pharmaco-
therapy, which is not taken into account in the RQLQ.
Furthermore, the difference between 12 SQ-HDM and placebo
was statistically significant for 4 of the 7 domains in the RQLQ:
nasal symptoms, nonnose/noneye symptoms, practical problems,
and impaired sleep. In addition, the 12 SQ-HDM group showed
improvement in all 4 symptoms included in the AR symptom
score: sneezing and blocked, itchy, and runny nose.
Regarding proper interpretation of the presented results, one
will notice a reduction over time in TCRSs and RQLQ scores
observed in all groups, including the placebo group (Fig 3), which
is consistent with the literature on AIT in general.33 This might
partially be caused by the free access to and personal guidance
in the use of standard-of-care pharmacotherapy. This means
that the improvement in the placebo group likely represents the
maximum that can be achieved through these means. The
differences from placebo in the active groups show that adding
the SQ HDM SLIT-tablet provides substantial and consistent
benefits not achieved by using standard-of-care pharmacotherapy
or specialist advice alone. Another contributing factor explaining
the observed reduction in the placebo group in addition to the
interventional study effect in general and a possible ‘‘placebo
effect’’ is the phenomenon of regression toward the mean. In
this trial subjects were selected based on high symptom score
and frequent use of pharmacotherapy at baseline.
Interestingly, despite the debate on the effectiveness of AIT in
polysensitized patients,34 this trial showed a statistically signifi-
cant effect for both active doses regardless of sensitization status.
This is consistent with a recent pooled post hoc analysis including
several studies on the SQ grass SLIT-tablet, suggesting that the
observed effects were not dependent on sensitization status.35
The presence of clinical symptoms to another perennial allergen
to which the subject is regularly exposed was an exclusion
criterion because other indoor sensitizations might interfere
during efficacy assessment periods.
It is clear from this trial that the SQ HDM SLIT-tablet reduces
HDM-induced AR symptoms and medication use, and in
addition, a more general effect on HDM-induced respiratorydisease can be expected. The SQ HDM SLIT-tablet has been
shown to be effective in reducing ICS use and the risk of asthma
exacerbations in patients with HDM-induced allergic asthma in a
phase II asthma trial36 and in a recent phase III trial (Virchow et al,
unpublished data), supporting the relevance of treating the
underlying HDM-induced respiratory allergic disease with the
SQ HDM SLIT-tablet, regardless of the dominant manifestation.
The potential for disease modification and long-term effect
when treating the underlying cause of the disease is a unique
feature for AIT compared with pharmacotherapy. The posttreat-
ment effect has not been investigated in this trial, but the
immunologic observations (to be published separately) are
similar to those observed of the previously developed SQ grass
SLIT-tablet, studies of which have confirmed the posttreatment
effect in grass pollen–induced allergic rhinoconjunctivitis.37
In conclusion, this trial confirmed the efficacy and favorable
safety profile of both doses of the SQ HDM SLIT-tablet in adults
with moderate-to-severe HDM-induced AR despite use of
pharmacotherapy. Although efficacy was seen for both doses,
the results were in general more robust for the 12 SQ-HDM dose.
The predefined criterion for clinical relevance was met for both
doses. Onset of action after 14 weeks and a sustained year-round
treatment effect were demonstrated.
The trial was funded by ALK, and in this context we thank the clinical trial
team at ALK for clinical project management, operational oversight, safety
monitoring, data management and statistics. Brian Hansen, ALK, was
responsible for medical writing, editorial, and journal submission assistance
for this manuscript.
Clinical implications: Efficacy results indicate that the SQ
HDM SLIT-tablet simultaneously reduces allergic rhinitis
symptoms and pharmacotherapy use in patients with
moderate-to-severe HDM-induced AR to a clinically relevant
degree.
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Main selection criteria were as follows:
d 18 to 65 years of age, with a clinical history consistent with moderate-
to-severe persistent HDM-induced AR (with or without asthma) for at
least 1 year before trial entry, with AR symptoms despite having
received symptomatic treatment;
d moderate-to-severe HDM-induced AR symptoms during the baseline
period defined as a daily total rhinitis symptom score of at least 6 or
a score of at least 5 with 1 severe symptom during at least 8 days of
the 15-day baseline period;
d use of symptomatic medication for treatment of HDM-induced AR dur-
ing at least 8 days of the 15-day baseline period;
d presence of 1 or more of the following Allergic Rhinitis and its Impact
on Asthma quality-of-life items caused by HDM-induced AR during
the baseline period:
1. sleep disturbance;
2. impairment of daily activities, leisure, and/or sport; and
3. impairment of school or work;
d daily use of ICSs should be 400 mg of budesonide or less or equivalent
if patient is asthmatic (ie, corresponding to Global Initiative for Asthma
treatment steps 1 or 2);
d positive skin prick test response (wheal diameter >_3 mm) to D pteronys-
sinus, D farinae, or both;
d positive specific IgE level against D pteronyssinus, D farinae, or both
(defined as IgE class >_2 [ie, >_0.70 kU/L]);
d no clinically relevant history of symptomatic seasonal allergic
rhinoconjunctivitis, asthma, or both caused by an allergen to which
the subject is regularly exposed and overlapping with the 8-week
efficacy assessment period;
d no reduced lung function (defined as FEV1 <70% of predicted value
after adequate pharmacologic treatment); and
d no clinical history of uncontrolled asthma within 3 months before
screening.
Intervention medication
The following pharmacotherapy for AR, conjunctivitis, or both was
provided to the subjects at randomization.
For rhinitis symptoms, the subjects were provided with oral antihistamine
tablets (desloratadine tablets, 5 mg) or nasal corticosteroid spray (budesonide
64 mg per dose).
For conjunctivitis symptoms, the subjects were provided with antihista-
mine eye drops (azelastine 0.05% or lodoxamide tromethamine 0.1% [in
Croatia only]). No eye drops were provided in Serbia. Instead, oral
antihistamine tablets were provided for conjunctivitis symptoms in Serbia.
Maximumdaily doses were 1 oral antihistamine tablet, 2 puffs per nostril of
nasal corticosteroid spray, and 2 drops per eye of antihistamine eye drops.
Randomization
The randomization list was divided into blocks of 6, with each block
comprising 2 sets of each of the 3 different treatments (ie, placebo, 6
SQ-HDM, or 12 SQ-HDM). In some cases the blocks were split when
distributed within countries.
End points and assessments
Primary and key secondary end points were daily scores averaged over the
8-week end-of-treatment efficacy assessment period.
Sample size
Power calculation was based on data from a previous trial of the SQ HDM
SLIT-tablet.E1 The observed mean of the TCRS for placebo was 4.9, and the
observed pooled SD of the TCRS was 4.02, which corresponded to a
coefficient of variation (SD/mean) of 0.82.
Further assumptions for the power calculations were as follows:
1. Analysis is performed based on multiple imputations, and subjects who
do not contribute any diary data during the last 8 weeks of treatment
will be imputed as sampled from the observed placebo distribution
of the TCRS.
2. Equal proportion of 10% is imputed in each treatment group.
3. The global hypothesis is tested with an F test on 2 df at the 5% level of
significance.
4. The pairwise hypotheses are tested with a 2-sided t test at a 5% level of
significance.
Based on these assumptions, the power to detect a difference from placebo
for 6 SQ-HDM and 12 SQ-HDM is presented in Table E2. The power
calculations were performed with computer simulations.
Because the mean TCRS value for placebo was assumed to be 4.9, the
relative difference of 20% and 25% used in the power calculations
corresponded to an absolute difference of 0.98 and 1.22, respectively.
In conclusion, based on the assumptions above, it is estimated that 300
randomized subjects per treatment group (ie, a total of 900 subjects) will
provide about 90% power to reject the global hypothesis of no difference
between any of the treatment groupswith an F test at a 5% level of significance
(Table E2). In other words, a difference between active treatment and placebo
can be detected with a power of about 90%.
Statistical methodology
All statistical tests were performed with SAS version 9.3 software (SAS
Institute, Cary, NC) with a 5% significance level, and all tests and 95% CIs
were 2-sided. The full analysis set represents all randomized subjects in
accordance with the ICH intent-to-treat principle.
The primary efficacy analysis was based on an LME model and performed
on the FASE2 by using a multiple imputation strategy for missing data by Ru-
bin (data set denoted FAS-MI).E3 Missing data in all treatment groups were
sampled from the observed data of the primary end point in the placebo group
by using the method of unrestricted random sampling with replacement.
The response variable in the LME was the square root of the TCRS, and
covariates included the average AR symptom score at baseline and country.
The primary outcome was the pairwise comparison between all 3 treatment
groups by using a t test in the LME model. The resulting P values were re-
ported together with the associated difference in (back-transformed) adjusted
means with 95% CIs.
The Fisher least significant difference procedureE2 was used to control for
multiplicity in the primary efficacy analysis. By using an F test in the LME
model, the first hypothesis to be tested was the global hypothesis of no differ-
ence inmeans between the 3 groups: placebo, 6 SQ-HDM, and 12 SQ-HDM. If
and only if this global hypothesis was rejected (P < .05), all pairwise compar-
isons between treatment groups were performed (12 SQ-HDM vs placebo, 6
SQ-HDM vs placebo, and 12 SQ-HDM vs 6 SQ-HDM).
Additional analyses of the primary end point included analyses using the
same LME model on subjects in the full analysis set with observations
(denoted FAS), on the PP set, and on FAS-MI by using the method of last
observation carried forward.
Multiplicity for the key secondary end points was controlled for by
hierarchic testing in the following order:
1. average total AR symptom score during the efficacy assessment period;
2. average total AR medication score during the efficacy assessment
period;
3. average overall RQLQ score during the efficacy assessment period;
and
4. average total combined allergic rhinoconjunctivitis score during the
efficacy assessment period.
The 4 key secondary hypotheses were first to be tested for 12 SQ-HDM and
then, if all were statistically significant, for 6 SQ-HDM. The key secondary
efficacy analyses were based on LME models and performed on the FAS-MI
for key secondary end points 1 and 2 and on FAS for all of the key secondary
end points.
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Secondary end points were analyzed on FAS. The statistical methods used
were LME models for continuous end points and generalized linear mixed
effect models for binary end points.
An absolute difference of 1 in TCRSmeans between the active treatment and
placebo groups was predefined as the minimal clinically relevant difference.
RESULTS
The results of the analysis of the primary end point (FAS-MI,
FAS, and PP) and the key secondary end points (FAS) are
presented in the main article. Table E3 shows the results of statis-
tical analysis for the 2 key secondary end points AR symptom
score and AR medication score based on FAS-MI.
Other secondary end points on rhinoconjunctivitis
and conjunctivitis
For all parameters, numerically lower scores were observed for
the actively treated groups compared with the placebo group. The
difference from placebo was statistically significant for the 12
SQ-HDM group for the rhinoconjunctivitis symptom score and
for the 6 SQ-HDM group for the rhinoconjunctivitis medication
score.
Summary statistics for the individual conjunctivitis symptoms
showed a lower raw mean score for the 12 SQ-HDM group than
for the placebo group for both conjunctivitis symptoms.
Binary secondary end points
Two binary end points were prespecified. One was the
proportion of symptom-free days during the efficacy assessment
period (ie, the last 8 weeks of the 1-year treatment period).
A symptom-free day was defined as a day with use of no
antihistamines (oral or ocular) and a rhinoconjunctivitis symptom
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score of 0. Nasal steroid was allowed because one recommended
use is as a daily controller.
The other binary end point was the proportion of subjects
responding ‘‘better’’ or ‘‘much better’’ to the end-of-treatment
global evaluation question on the comparison of rhinitis symp-
toms during the year with treatment with symptoms in the
previous year. The odds for being in the ‘‘improved’’ category
in the global evaluation were numerically higher in the active
groups than in the placebo group, and this was statistically
significant for the 6 SQ-HDM group. The odds for having a
symptom-free day were statistically significantly higher in the
actively treated groups than in the placebo group, but the overall
proportion of symptom-free days was low.
Safety: Summary of adrenaline case
One subject from the 12 SQ-HDM group received adrenaline
after the first tablet because of a mild local allergic reaction.Within
5 minutes of the first administration of the IMP, the subject
experienced laryngeal edema (reported by the investigator as very
mild laryngeal edema, no vital risk). Treatment included
adrenaline, methylprednisolone, and desloratadine. All symptoms
abated after 30 minutes. The subject subsequently continued and
completed the trial without otherAEs, except formild oral pruritus.
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Runny nose 0-3 0-3 0-3
Blocked nose 0-3 0-3 0-3
Sneezing 0-3 0-3 0-3
Itchy nose 0-3 0-3 0-3
Red/itchy eyes 0-3 0-3 0-3
Watery eyes 0-3 0-3 0-3
Oral antihistamine 0-4 0-4 0-2 0-2 0-6
Ocular antihistamine 0-6 0-6 0-6
Nasal steroid 0-8 0-8 0-8
Total 0-24 0-12 0-12 0-6 0-8 0-14 0-38
Symptom scores: 0, no; 1, mild; 2, moderate; and 3, severe. Rhinitis medication scores: oral antihistamine (desloratadine tablets, 5 mg): 4 per tablet, nasal steroid (budesonide nasal
spray, 64 mg/dose), 2 per puff. Conjunctivitis medication score: oral antihistamine (desloratadine tablets, 5 mg): 2 per tablet, ocular antihistamine (azelastine eye drops, 0.05%): 1.5
per drop. Maximum daily medication use: 1 oral antihistamine tablet, 2 puffs per nostril of nasal corticosteroid spray, 2 antihistamine eye drops per eye.
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TABLE E2. Power for statistical analysis based on imputation
Hypotheses to be rejected
Difference from placebo to be
detected
No. total Power to reject6 SQ-HDM 12 SQ-HDM
H0,1:placebo 5 6SQ-HDM 5 12 SQ-HDM 20% 25% 900 90%
H0,1:placebo 5 6SQ-HDM 5 12 SQ-HDM and H0,2: placebo 5 12 SQ-HDM 20% 25% 900 88%
H0,1: placebo 5 6 SQ-HDM 5 12 SQ-HDM and H0,3: placebo 5 6 SQ-HDM 20% 25% 900 75%
H0,1: placebo5 6 SQ-HDM5 12 SQ-HDM and H0,2: placebo5 12 SQ-HDM
and H0,3: placebo 5 6 SQ-HDM
20% 25% 900 73%
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TABLE E3. Key secondary results for FAS-MI during the efficacy assessment period
Key secondary end point Treatment No. Adjusted means Absolute difference (95% CI) P value
AR symptom score Placebo 338 3.31 — —
6 SQ-HDM 336 2.94 0.38 (0.01-0.74) .042
12 SQ-HDM 318 2.84 0.47 (0.11-0.82) .001
AR medication score Placebo 338 2.86 — —
6 SQ-HDM 336 2.23 0.63 (0.11-1.15) .017
12 SQ-HDM 318 2.32 0.54 (0.01-1.07) .045
Boldface numbers indicate a confirmatory result according to the multiplicity adjusting procedure.
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TABLE E4. Secondary end points on rhinoconjunctivitis and conjunctivitis in the efficacy assessment period (FAS)
End point Treatment group No. Adjusted mean Absolute difference (95% CI) P value
Rhinoconjunctivitis symptom score (n 5 879) Placebo 298 4.24 — —
6 SQ-HDM 297 3.84 0.40 (20.10 to 0.89) .118
12 SQ-HDM 284 3.56 0.68 (0.19 to 1.17) .006
Rhinoconjunctivitis medication score (n 5 754)* Placebo 257 3.87 — —
6 SQ-HDM 256 2.95 0.92 (0.19 to 1.65) .013
12 SQ-HDM 241 3.23 0.65 (20.12 to 1.41) .097
Combined conjunctivitis score (n 5 754)* Placebo 257 1.98 — —
6 SQ-HDM 256 1.76 0.21 (20.13 to 0.55) .220
12 SQ-HDM 241 1.79 0.19 (20.15 to 0.53) .279
Conjunctivitis symptom score (n 5 879) Placebo 298 0.76 — —
6 SQ-HDM 297 0.75 0.01 (20.15 to 0.17) .898
12 SQ-HDM 284 0.63 0.13 (20.02 to 0.29) .087
Conjunctivitis medication score (n 5 754)* Placebo 257 0.90 — —
6 SQ-HDM 256 0.71 0.19 (20.01 to 0.39) .065
12 SQ-HDM 241 0.72 0.19 (20.02 to 0.39) .077
*Antihistamine eye drops were unavailable in 2 countries and thus not scored.
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TABLE E5. Binary secondary end points in the efficacy assessment period (FAS)
End point Treatment group No. Estimated probability (% [95% CI]) Odds ratio (active over placebo [95% CI]) P value
Symptom-free days Placebo 298 0.7% (0.4% to 1.3%) — —
6 SQ-HDM 297 1.6% (0.9% to 2.9%) 2.33 (1.32 to 4.13) .004
12 SQ-HDM 284 1.6% (0.9% to 2.9%) 2.28 (1.28 to 4.07) .005
Global evaluation (% improved) Placebo 299 68.0% (56.9% to 77.3%) — —
6 SQ-HDM 300 76.1% (66.3% to 83.8%) 1.50 (1.04 to 2.16) .029
12 SQ-HDM 284 75.1% (65.0% to 83.0%) 1.42 (0.98 to 2.05) .062
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TABLE E6. Overview of AEs in the trial
Treatment group
Placebo (n 5 338) 6 SQ-HDM (n 5 336) 12 SQ-HDM (n 5 318) Active all (n 5 654) Overall (n 5 992)
No. (%) E (%) No. (%) E (%) No. (%) E (%) No. (%) E (%) No. (%) E (%)
All AEs 154 (46) 327 (100) 212 (63) 678 (100) 213 (67) 681 (100) 425 (65) 1359 (100) 579 (58) 1686 (100)
Causality
Unlikely 128 (38) 231 (71) 128 (38) 277 (41) 121 (38) 224 (33) 249 (38) 501 (37) 377 (38) 732 (43)
Possible 50 (15) 96 (29) 161 (48) 401 (59) 167 (53) 457 (67) 328 (50) 858 (63) 378 (38) 954 (57)
Severity of all AEs
Mild 119 (35) 235 (72) 186 (55) 509 (75) 184 (58) 505 (74) 370 (57) 1014 (75) 489 (49) 1249 (74)
Moderate 56 (17) 82 (25) 83 (25) 157 (23) 78 (25) 168 (25) 161 (25) 325 (24) 217 (22) 407 (24)
Severe 10 (3) 10 (3) 10 (3) 12 (2) 7 (2) 8 (1) 17 (3) 20 (1) 27 (3) 30 (2)
Severity of IMP-related AEs
Mild 41 (12) 77 (80) 147 (44) 351 (88) 149 (47) 364 (80) 296 (45) 715 (83) 337 (34) 792 (83)
Moderate 13 (4) 19 (20) 27 (8) 47 (12) 37 (12) 87 (19) 64 (10) 134 (16) 77 (8) 153 (16)
Severe — — 3 (<1) 3 (<1) 5 (2) 6 (1) 8 (1) 9 (1) 8 (<1) 9 (<1)
Seriousness
Serious 8 (2) 8 (2) 4 (1) 4 (<1) — — 4 (<1) 4 (<1) 12 (1) 12 (<1)
Nonserious 151 (45) 319 (98) 212 (63) 674 (>99) 213 (67) 681 (100) 425 (65) 1355 (>99) 576 (58) 1674 (>99)
Change to IMP
None 135 (40) 277 (85) 194 (58) 596 (88) 195 (61) 595 (87) 389 (59) 1191 (88) 524 (53) 1468 (87)
Temporary interruption 29 (9) 42 (13) 45 (13) 68 (10) 38 (12) 59 (9) 83 (13) 127 (9) 112 (11) 169 (10)
Discontinued 7 (2) 8 (2) 10 (3) 14 (2) 13 (4) 27 (4) 23 (4) 41 (3) 30 (3) 49 (3)
Outcome
Recovered 150 (44) 308 (94) 209 (62) 659 (97) 211 (66) 671 (99) 420 (64) 1330 (98) 570 (57) 1638 (97)
Recovered with sequelae 1 (<1) 1 (<1) — — — — — — 1 (<1) 1 (<1)
Not recovered 13 (4) 15 (5) 14 (4) 18 (3) 6 (2) 8 (1) 20 (3) 26 (2) 33 (3) 41 (2)
Unknown 3 (<1) 3 (<1) 1 (<1) 1 (<1) 2 (<1) 2 (<1) 3 (<1) 3 (<1) 6 (<1) 6 (<1)
Leading to discontinuation
Yes 7 (2) 8 (2) 10 (3) 14 (2) 13 (4) 28 (4) 23 (4) 42 (3) 30 (3) 50* (3)
No 151 (45) 319 (98) 205 (61) 664 (98) 207 (65) 653 (96) 412 (63) 1317 (97) 563 (57) 1636 (97)
E, Number of events.
*One of the AEs leading to discontinuation from the trial was concomitantly reported by the investigator as leading to a temporary interruption of IMP. Thus this AE is only
included in the number of AEs leading to discontinuation from the trial and not in the number of AEs leading to a discontinuation of IMP.
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